Development of blood collection tubes for glucose measurement using adenosine 3-phosphate and sodium fluoride as glycolytic inhibitors
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · 2024
DOI: 10.1177/00045632231194829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2024. Verfasst von Yukio Kume und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry, Graduate School of Health and Social Services, Saitama Prefectural University, Koshigaya, Japan. Hauptthemen laut MEDLINE: Sodium Fluoride, Blood Glucose. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Joint research grant from the University of Tokyo and Nipro Corporation..
Abstract (Originalsprache)
Background
Blood collection tubes with sodium fluoride (NaF) added as a glycolytic inhibitor are widely used for glucose measurement. However, the glycolytic inhibitory effects of NaF are insufficient, and decreases in glucose levels over time after blood collection have become a problem.
Methods
Blood from a volunteer collected using an NaF tube was used to compare the glycolysis inhibitory abilities of ATP and ADP. Blood samples from 10 volunteers were collected in NaF tubes and NaF tubes with added ATP (NaF–ATP tubes). The stability of glucose and haemoglobin (Hb)A1c after whole-blood storage from immediately after blood collection to 24 h later was compared.
Results
ATP and ADP had similar inhibitory effects on glycolysis, but ATP was selected as an additive for blood collection tubes because ADP was more haemolytic than ATP. We verified the ability of NaF blood collection tubes supplemented with ATP to inhibit glycolysis. Mean (± standard deviation) glucose levels (n=10) after storage for 24 h after blood collection decreased to −9.0 ± 2.7 mg/dL (−0.50 ± 0.15 mmol/L) in conventional NaF tubes. NaF–ATP(20) tubes with 20 mg (0.036 mmol) ATP added showed a reduced decrease, with a mean of −5.8 ± 2.9 mg/dL (−0.32 ± 0.16 mmol/L). NaF–ATP tubes also had no effect on HbA1c measurement.
Conclusion
This study reports on a blood collection tube that enables the measurement of glucose and HbA1c. Based on the results of validation, we conclude that NaF–ATP tubes can reduce decreases in glucose over time in stored whole blood compared to conventional NaF tubes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Chemistry, Graduate School of Health and Social Services, Saitama Prefectural University, Koshigaya, Japan.
- Department of Clinical Laboratory, The University of Tokyo Hospital, Bunkyo-ku, Japan.
- Department of Health Sciences, Graduate School of Health and Social Services, Saitama Prefectural University, Koshigaya, Japan.
ORCID-Profile: Yukio Kume, Yuji Hirowatari, Makoto Kurano
Förderung
- Joint research grant from the University of Tokyo and Nipro Corporation.
Zitieren
APA
Kume, Y., Hirowatari, Y., Kurano, M., Yatomi, Y., & Matsushita, M. (2024). Development of blood collection tubes for glucose measurement using adenosine 3-phosphate and sodium fluoride as glycolytic inhibitors. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. https://doi.org/10.1177/00045632231194829
Vancouver
Kume Y, Hirowatari Y, Kurano M, Yatomi Y, Matsushita M. Development of blood collection tubes for glucose measurement using adenosine 3-phosphate and sodium fluoride as glycolytic inhibitors. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2024. doi:10.1177/00045632231194829
BibTeX
@article{Kume2024,
author = {Kume, Yukio and Hirowatari, Yuji and Kurano, Makoto and Yatomi, Yutaka and Matsushita, Makoto},
title = {Development of blood collection tubes for glucose measurement using adenosine 3-phosphate and sodium fluoride as glycolytic inhibitors},
journal = {Annals of Clinical Biochemistry: International Journal of Laboratory Medicine},
year = {2024},
doi = {10.1177/00045632231194829}
}
EUVIMED